Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485968 | 0.98 | ALDH1A1 (0.50) | ALDH1A1DNM1SRD5A2HTTSMN1; SMN2 | |
| Bromide SCHEMBL232863 | 0.94 | DNM1 (0.43) | ALDH1A1DNM1SRD5A2HTTSMN1; SMN2 | |
| Bromide SCHEMBL231806 | 0.94 | DNM1 (0.43) | ALDH1A1DNM1SRD5A2HTTSMN1; SMN2 | |
| Bromide SCHEMBL231434 | 0.92 | DNM1 (0.59) | ALDH1A1DNM1SRD5A2HTTSMN1; SMN2 | |
| Bromide SCHEMBL29669478 | 0.92 | DNM1 (0.51) | ALDH1A1DNM1SRD5A2HTTSMN1; SMN2 | |
| SCHEMBL321584 | 0.92 | ALDH1A1 (0.44) | ALDH1A1DNM1SRD5A2HTTSMN1; SMN2 | |
| SCHEMBL487054 | 0.92 | ALDH1A1 (0.44) | ALDH1A1DNM1SRD5A2HTTSMN1; SMN2 | |
| SCHEMBL16731588 | 0.92 | DNM1 (0.51) | ALDH1A1DNM1SRD5A2HTTSMN1; SMN2 | |
| Bromide SCHEMBL4003015 | 0.91 | ACHE (0.45) | ALDH1A1DNM1SRD5A2HTTSMN1; SMN2 | |
| Bromide SCHEMBL6055899 | 0.91 | DNM1 (0.41) | ALDH1A1DNM1SRD5A2HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120114655-A | Delivery of hydrophobic active agent particles | 苏尔莫迪克斯公司 | 2025-06-10 | — | — | CN | claimed |
| EP-4514346-A1 | MEDICAL DEVICE COATINGS WITH MICROCRYSTALLINE ACTIVE AGENTS | SurModics, Inc. (US) | 2025-03-05 | — | — | EP | claimed |
| US-12083249-B2 | Delivery of hydrophobic active agent particles | SURMODICS, INC. (US) | 2024-09-10 | — | — | US | claimed |
| WO-2023211937-A1 | MEDICAL DEVICE COATINGS WITH MICROCRYSTALLINE ACTIVE AGENTS | SURMODICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230338623-A1 | MEDICAL DEVICE COATINGS WITH MICROCRYSTALLINE ACTIVE AGENTS | BANK OF MONTREAL, AS COLLATERAL AGENT | 2023-10-26 | — | — | US | claimed |
| US-20230338622-A1 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | BANK OF MONTREAL, AS COLLATERAL AGENT | 2023-10-26 | — | — | US | claimed |
| US-11529440-B2 | Delivery of hydrophobic active agent particles | SURMODICS, INC. (US) | 2022-12-20 | — | — | US | claimed |
| EP-3250249-B1 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | SURMODICS INC (US) | 2021-12-08 | — | — | EP | claimed |
| US-20200237971-A1 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | BANK OF MONTREAL, AS COLLATERAL AGENT | 2020-07-30 | — | — | US | claimed |
| US-9861727-B2 | Delivery of hydrophobic active agent particles | SURMODICS, INC. (US) | 2018-01-09 | — | — | US | claimed |
| US-20060240072-A1 | Side effect reduction of implanted medical devices by coating the surface with a curable mixture or solution of a photoinitiator and a crosslinkable macromer with pendant polymerizable groups; nontoxicity, efficiency, and solubility; drug delivery, cellular immune isolation, tissue repair | SURMODICS, INC. | 2006-10-26 | — | — | US | claimed |
| EP-1465740-A4 | REAGENT AND METHOD FOR PROVIDING COATINGS ON SURFACES | SURMODICS INC (US) | 2006-06-07 | — | — | EP | claimed |
| US-7041174-B2 | Grafting apparatus and method of using | SUNMODICS,INC. (US) | 2006-05-09 | — | — | US | claimed |
| EP-1594623-A1 | GRAFTING APPARTUS AND METHOD OF USING | SurModics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| JP-2005514192-A | — | — | 2005-05-19 | — | — | JP | claimed |
| EP-1465740-A1 | REAGENT AND METHOD FOR PROVIDING COATINGS ON SURFACES | SurModics, Inc. (US) | 2004-10-13 | — | — | EP | claimed |
| WO-2004073885-A1 | GRAFTING APPARTUS AND METHOD OF USING | SURMODICS, INC. (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040161547-A1 | Grafting apparatus and method of using | SURMODICS, INC. | 2004-08-19 | — | — | US | claimed |
| US-20030165613-A1 | Reagent and method for providing coatings on surfaces | Surmodics Coatings, LLC | 2003-09-04 | — | — | US | claimed |
| WO-2003055611-A1 | REAGENT AND METHOD FOR PROVIDING COATINGS ON SURFACES | SURMODICS, INC. (US) | 2003-07-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338622-A1 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | AHR, KRT18, CD44 | ACHE 845/4885ALDH1A1 64/4885DNM1 4016/4885 |
| US-20200237971-A1 | DELIVERY OF HYDROPHOBIC ACTIVE AGENT PARTICLES | AHR, KRT18, CD44 | ACHE 845/4885ALDH1A1 64/4885DNM1 4016/4885 |
| US-12083249-B2 | Delivery of hydrophobic active agent particles | AHR, KRT18, CD44 | ACHE 845/4885ALDH1A1 64/4885DNM1 4016/4885 |
| US-11529440-B2 | Delivery of hydrophobic active agent particles | AHR, KRT18, CD44 | ACHE 845/4885ALDH1A1 64/4885DNM1 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.